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List of abbreviations: 
HE : Hemangioendothelioma 
EOMA : Mouse Hemangioendothelioma Endothelial Cells. 
MAE : mouse aortic endothelial cells. 
XRT : X-ray therapy 
NBE : Natural berry extract 
FDA : Food and Drug Administration 
IND : Investigational New Drug 
NIOSH : National Institute for Occupational Safety and Health 
ATP : Adenosine triphosphate 
OCR : Oxygen consumption rate 
ECAR : extracellular acidification rate 
Drp1 : Dynamin-related protein 
Mfn2 : Mitofusin 2  
SIRT3 : sirtuin-3 
AMPK : AMP-activated protein kinase 
DMSO : Dimethyl sulfoxide  
DMEM : Dulbecco's Modified Eagle Medium 
FBS : Fetal bovine serum 
























































































































































































































































Aims: Hemangioendothelioma (HE) may be benign or malignant. EOMA cells are validated 
to study mechanisms in HE. This work demonstrates that EOMA cells heavily rely on 
mitochondria to thrive. Thus, a combination therapy including weak X-ray therapy (XRT, 
0.5Gy) and a standardized natural berry extract (NBE) that is known to be effective in 
managing experimental HE and has been awarded with Food and Drug Administration - 
Investigational New Drug Application (FDA-IND # 140318) for studies on infantile 
hemangioma was tested.  
Results: NBE treatment alone selectively attenuated basal oxygen consumption rate (OCR) 
of EOMA cells. NBE significantly sensitized EOMA, but not MAE, cells to XRT-dependent 
attenuation of mitochondrial respiration and ATP production. Combination treatment 
selectively and potently influenced mitochondrial dynamics in EOMA cells such that fission 
was augmented. Markers of mitochondrial fission were induced by the said combination 
therapy. This was achieved by lowering of mitochondrial Sirtuin 3 (SIRT3) causing increased 
phosphorylation of AMP-activated protein kinase (AMPK). A key role of SIRT3 in loss of 
EOMA cell viability caused by the combination therapy was evident when pyrroloquinoline 
quinone, an inducer of SIRT3, pre-treatment rescued these cells.  
Innovation and Conclusion: Mitochondria-targeting NBE significantly extended survival of 
HE-affected mice. The beneficial effect of combination therapy was, however, far more 
potent with 3-fold increase in murine survival. Mitochondria-targeted antitumor therapies 
























































































































































































































































Clinically presented as vascular neoplasms, hemangioendothelioma (HE) may also display 
characteristics intermediate between entirely benign hemangiomas and highly malignant 
angiosarcomas (38,59,63). In children, they frequently cause deformity and can cause 
death. Kaposiform hemangioendothelioma features several solid poorly circumscribed 
nodules such that each nodule is composed of a mixture of small capillaries and solid 
lobules of endothelial cells arranged in a glomeruloid pattern. EOMA cells are a validated 
experimental model to study mechanisms in HE and its management (11,12,23).   
Mitochondrial functionality is a critical requirement for tumor anabolism. The growth of 
neoplastic tissue is supported by a hyperactive glycolytic machinery, often anaerobic. It is 
commonly accepted that pyruvate, thus generated in the cytoplasm, is shunted to produce 
lactate via lactate dehydrogenase. It has been thus assumed that tumor cells are limited in 
their capacity for oxidative phosphorylation (OXPHOS). Such notion would assign low value 
to mitochondrial functionality for its significance in supporting tumor anabolism(51) . 
More recent work, however, appreciates that tumor metabolism is less homogenous than 
was previously imagined (51). Thorough characterization of the metabolic process involved 
in tumor has now identified tumorigenic cell populations that are heavily reliant on 
mitochondrial respiration compared to their dependence on glycolysis. Mitochondrial 
depletion of cancer cells markedly limited tumorigenic potential (13,25,37,60). Loss of 
mitochondrial respiration causes proliferating cancer cells to become functionally limited 
for electron acceptors(50) .  
Recent literature suggest an essential role of mitochondria in cancer. Cancer cells devoid 
of mitochondrial DNA (mtDNA) lose tumorigenic potential unless OXPHOS is reconstituted 
in these cells by mitochondria acquired from host stroma (7). Furthermore, defects in 
OXPHOS sensitized tumor cells to cytotoxic drugs (13,53). Conventional radiation therapy 
is known to compromise tumor mitochondrial function (44). Targeting mitochondrial 
function has emerged as a viable strategy for the development of novel anticancer agents. 
Cytotoxic drugs, the cornerstone for chemotherapy, however, are notorious for their 


























































































































































































































































Institute for Occupational Safety and Health (NIOSH) as hazardous drugs as they threaten 
the health of an estimated 8 million U.S. healthcare workers. 
Berry polyphenols have been recognized for their chemopreventive properties (40,52). 
Low fruit and vegetable intake is a known contributor to cancer related deaths (5,58). On 
the other hand, specific phytochemicals such as anthocyanins are known to act on a 
number of specific molecular mechanisms that inhibit tumorigenesis (56). Our recent work 
has identified that a standardized anthocyanin-rich natural berry extract (NBE) is effective 
in prolonging survival of HE bearing mice (11). The objective of this work is to investigate 
tumor mitochondrial function and its significance in the development of HE as well as in 
the survival of HE-bearing mice. NBE and therapeutic gamma X-ray radiation (XRT) have 
been tested, alone or together in low dosages to study potential interaction, for their 
ability to target mitochondrial respiration in tumor cells.  
Results: 
Sensitization of tumor forming endothelial cells to effects of XRT is time and dose 
dependent.  To determine the dose and duration of NBE and XRT exposure, cell toxicity 
studies were performed. The NBE dose (200 µg/ml) and pre-treatment duration were 
determined using previously reported toxicity and dose response studies for EOMA cells 
(4). Non-tumor forming murine aortic endothelial (MAE) cells were used as controls 
(11,12).Time and dose responses to XRT were analyzed using LDH and PI exclusion assays 
to identify the threshold dose of XRT needed to induce cell toxicity (Figs. 1a-b). XRT dose 
with 1.0 Gy (24h) was toxic in MAE cells (Fig 1a). This toxicity was, however, not observed 
using LDH leakage assay (Fig 1b) which is known to be less sensitive than flow-cytometry 
based PI assay (15). EOMA cells, on the other hand, were sensitive to NBE treatment alone 
(Fig. 1a-b), as demonstrated by both PI exclusion as well as LDH leakage assays. 
Interestingly, NBE pretreatment sensitized EOMA cells to weak XRT (0.5Gy) mediated 
toxicity. Since weak XRT alone in EOMA cells did not induce toxicity, NBE pretreatment 
followed by a regimen of weak XRT was selected as the threshold condition to induce cell 
























































































































































































































































NBE sensitized EOMA, not MAE, cells to weak XRT by inhibiting mitochondrial 
respiration. Compared to MAE, EOMA cells displayed high basal mitochondrial oxygen 
consumption rate (OCR; Fig 2a). NBE treatment alone selectively attenuated basal OCR of 
EOMA cells. This reduction of OCR was not observed in MAE cells (Fig. 2a,d). Elevated 
basal OCR in EOMA, compared to MAE, was evident even after exposure to weak XRT. 
Interestingly, weak XRT was observed to offset the effect of NBE in attenuating 
mitochondrial respiration (Fig. 2b&d). Of note, this opposing effect of XRT on NBE was 
transient and did not hold over time (Fig. 2b&d). On the contrary, over time (6-12h), NBE 
significantly sensitized EOMA, but not MAE, cells to XRT (Fig. 2c-d). This observation was 
consistent with findings on EOMA cell toxicity in response to a combination of NBE and 
weak XRT (Fig 1a-b). MAE cells remained safely unresponsive to such combination 
treatment (Fig. 2d). 
Inhibition of tumor cell glycolysis 
Extracellular acidification rate (ECAR) is a measure of cellular glycolytic rate (27). EOMA 
cells displayed 3-fold high basal ECAR than healthy MAE cells (Fig. 3a,d). Thus, glycolysis is 
hyperactive in EOMA cells. NBE successfully compromised the path of glycolytic energy 
supply specifically in EOMA, but not in MAE, cells at lower dosage of radiation (Fig. 3a,d). 
This effect of NBE, taken together with its inhibitory effect of mitochondrial respiration as 
addressed above, does achieve substantial functional significance as reflected by the loss 
of EMOA cell viability (Fig. 1). As it relates to the study of healthy MAE, weak XRT 
accelerated glycolysis (Fig. 3b-d). In contrast, weak XRT had no effect on its own on EOMA 
cells (Fig. 3b-d). Interestingly, NBE was effective in inhibition of glycolysis specifically in 
EOMA cells. Of note, in combination with weak XRT such inhibition of glycolysis was 
significantly potentiated (Fig. 3b-d).  
Blunted cellular respiration and reduced ATP production in EOMA cells. Further studies 
tested the combination of NBE and weak XRT both of which are known to be safe for 
healthy MAE (Fig. 1). The study of cellular bioenergetics showed that both NBE, XRT and 
their combination had no deleterious effect on MAE cells (Fig. 4a). Basal OCR in EOMA 


























































































































































































































































(Fig. 4a). To dissect non-mitochondrial respiration from overall OCR, antimycin A and 
rotenone were used as inhibitors of complexes III and I, respectively (15). Residual oxygen 
consumption was 2-fold higher in EOMA compared to MAE cells (Fig. 4b). NBE treatment 
causes significant decrease in the residual oxygen consumption specifically in EOMA cells. 
Weak XRT alone was more effective than NBE in inhibiting non-mitochondrial respiration. 
However, a combination of NBE and weak XRT acted co-operatively to specifically inhibit 
non-mitochondrial respiration of EOMA cells (Fig. 4b). Productivity of mitochondrial 
respiration in EOMA cells was determined by ATP generated through OXPHOS in support 
of tumor anabolism. EOMA cells demonstrated a 5-fold higher rate of ATP production than 
that in healthy MAE cells (Fig. 4c). Such high rate of ATP production remained unaffected 
by weak XRT. NBE was potent in blunting the rate of ATP production specifically in EOMA 
cells. However, in combination with otherwise ineffective weak XRT the effect of NBE was 
potentiated such that an estimated two-third of the rate of ATP production was inhibited 
(Fig. 4c). Although basal ATP production rate in EOMA was much higher than that of MAE 
as reported above, total ATP balance in EOMA cells were roughly half of those measured in 
MAE (Fig. 4d). This finding hints towards a very high rate of ATP consumption in EOMA, 
consistent with its much higher growth rate compared to MAE. NBE, but not weak XRT 
alone, further depleted ATP levels specifically in EOMA cells. Although ATP levels in EOMA 
cells were lower than that in MAE cells, the ATP/ADP ratio were comparable. This ratio 
was markedly decreased in response to NBE. While weak XRT alone did not influence this 
ratio, together with NBE it further elevated ADP levels in a way that the ratio was further 
decreased (Fig. 4e-f).  
Mitochondrial fission and membrane potential. Morphological evidences by electron 
microscopy shows more abundance of mitochondria in EOMA compared to MAE 
(Supplementary Fig. 1). NBE induces dynamin-related protein 1 (Drp1), a marker of 
mitochondrial fission protein, in both MAE as well as EOMA (Fig 5a,b,c, Supplementary 
Figs. 2, 3). Recruitment of Drp1 to mitochondrial tubular network was clearly seen in 
EOMA cells, however fragmentation was not complete (Fig S2). In the presence of weak 
XRT, such induction was abrogated in MAE but not in EOMA (Fig 5b,c, Supplementary Fig. 























































































































































































































































cells compared to MAE (Fig. 5b,d). In MAE, not NBE but weak XRT induced Mfn-2. Such 
weak XRT-dependent induction was blunted in the presence of NBE (Fig. 5b,d). Increased 
expression of mitochondrial fission factor (MFF) and simultaneously decreased dynamin-
like protein (OPA1) expression indicate fission in response to combined treatment of NBE 
and weak XRT (Fig S4). Basal mitochondrial copy number in EOMA cells were high 
compared to MAE (Fig 5e).  Exposure to NBE reduced the mitochondrial copy number 
selectively in EOMA but not in MAE (Fig 5e). This effect was consistent with exposure to 
XRTweak and combination of NBE+ XRTweak (Fig 5e). In EOMA cells with higher baseline levels 
of Mfn-2 compared to MAE, NBE lowered the expression of Mfn-2. Interestingly, in these 
cells, NBE and weak XRT acted co-operatively in markedly lowering the abundance of Mfn-
2 (Fig. 5b,d). Studies testing additional parameters aimed at rigor showed decreased 
mitochondrial fusion marker protein (OPA1) and increased mitochondrial fission marker 
protein (MFF) in response to NBE or NBE+XRTweak combined treatment (Supplementary 
Fig. 4).  
Depolarization of the mitochondrial membrane potential (ΔΨm) is a hallmark of 
compromised mitochondrial function (65). Flow cytometric analyses of mitochondrial ΔΨm 
revealed that EOMA cells demonstrate 3-fold higher mitochondrial membrane potential 
under basal conditions compared to that in MAE (Fig. 5f-i). In MAE, neither NBE nor weak 
XRT displayed any effect on mitochondrial membrane potential. However, in EOMA cells, 
NBE potently compromised mitochondrial membrane potential. Such deleterious effect of 
NBE on mitochondrial function of EOMA cells was markedly enhanced by the combined 
treatment of weak XRT (Fig. 5f-i). Neither caspase 3 cleavage nor the expression of its 
upstream regulator caspase 9 were  responsive to a combined treatment with NBE and 
weak XRT (Fig. S3) ruling out the involvement of this particular apoptotic pathway.  
Low SIRT3 induces death of EOMA cells.  SIRT3 is a mitochondrial protein that contributes 
to cell survival by a number of mechanisms including regulation of mitochondrial dynamics 
(3,6,32,43). Abundance of SIRT3 protein was markedly lower in EOMA cells compared to 
that in MAE (Fig. 6a). NBE treatment selectively depleted SIRT3 in EOMA cells, but not that 
in MAE. In combination with weak XRT, NBE was even more potent in depleting SIRT3 























































































































































































































































EOMA cells, pyrroloquinoline quinone (PQQ), a potent inducer of SIRT3, was studied (62). 
PQQ induced SIRT3 in both cells but the magnitude of induction was much higher in EOMA 
cells (Fig. 6c). The 20 µM dose was chosen for further studies as tangible cytotoxicity was 
detected with higher dosage (Fig. 6d). PQQ treatment restored SIRT3 in EOMA cells 
treated with a combination of NBE and weak XRT (Fig. 6f). Such restoration of SIRT3 
abrogated the cytotoxic properties of the combination of NBE and weak XRT (Fig. 6e). 
These findings support the contention that in EOMA cells, SIRT3 depletion causes cell 
death. Further evidence to rigorously test that contention, a SIRT3 inhibitor LC-0296(1), 
was utilized. LC-0296 potently depleted SIRT3 in EOMA cells (Fig. 6g). Such severe 
depletion alone caused EOMA cell death in a way that was more severe than effect of NBE. 
Taken together, neutralizing SIRT3 is productive in killing EOMA cells.  The combination of 
NBE and weak XRT exploits that avenue of tumor cell death.  
AMPK phosphorylation caused by severe depletion of SIRT3 compromises mitochondrial 
respiration in EOMA cells. Induction of SIRT3 by PQQ lowered phospho-AMPK abundance 
in both MAE as well as EOMA cells (Fig. 7a). Inverse relationship between abundance of 
SIRT3 and phospho-AMPK was also evident in studies comparing MAE with EOMA. In 
EOMA, low SIRT3 was associated with high phospho-AMPK (Fig. 7b-c). Phospho-AMPK is 
expressed in a way that is normalized by the overall abundance of AMPK under those 
conditions. As reported above, NBE treatment compromised mitochondrial function as 
well as marginally depleted SIRT3 in EOMA cell yet under these conditions phospho-AMPK 
remained unaffected. However, under conditions of combination treatment with NBE and 
weak XRT severe depletion of SIRT3 (Fig. 6a) elevated phospho-AMPK (Fig. 7b-c). PQQ 
rescued against loss of mitochondrial respiration in EOMA cells treated with a combination 
of NBE and weak XRT (Fig. 7d). Consistently, rescue against loss of membrane potential 
was also evident in response to PQQ treatment (Fig. 7e). These observations argue in favor 
of a critical role of SIRT3 depletion in causing AMPK phosphorylation followed by 
mitochondrial dysfunction. Thus, AMPK phosphorylation caused by severe depletion of 
SIRT3 compromises mitochondrial respiration in EOMA cells. 
Improved survival of mice with HE tumor. To determine the functional impact of 























































































































































































































































the control arm received hyaluronic acid cream (29) topically and water orally as vehicle 
control. The three treatment arms included the following: topical and oral NBE treatment 
also known as the NBE arm; 7.5 Gy XRT over three days or weak XRT directed at the tumor 
in 3 fractionated doses; and a combination of the above two also known as the NBE + 
weak XRT combination treatment group. Tumor volume and blood velocity were 
determined by Doppler ultrasound (Fig. 8a). Tumors in all treatment groups were of the 
same size on day 3 following EOMA cell injection before beginning any of the therapeutic 
interventions. In the control arm, rapid increase in tumor volume was noted in 10 days. In 
this group, the first death was also registered on day 10. Both NBE as well as weak XRT 
alone significantly limited tumor volume. This effect was most prominent in the 
combinations treatment group (Fig. 8b). As expected, the changes in blood flow velocity 
showed the same pattern of response as seen with tumor size (Fig. 8c). The tumors were 
also qualitatively different between treatment groups with control animals having large 
firm slightly spongy blood-filled tumors that had abundant tumor parenchyma and stroma. 
Irradiated tumors were fluid filled sacs with minimal tumor stroma and no appreciable 
parenchyma. NBE treated mice had small firm tumors with minimal tumor parenchyma 
and stroma. NBE and XRT had a fluid filled sac but no appreciable tumor parenchyma or 
stroma (Figs. 8d-e). A Kaplan-Meier survival curve was done in a separate cohort of mice 
which received the same treatment protocols and results were consistent with the other in 
vivo measurements showing a progressive increase in survival from control, NBE only, 
weak XRT only, and NBE with XRT (Fig. 8f). Thus, both NBE and XRT were able to prolong 
survival in these mice with the combination of the two treatments being the most 
effective. 
DISCUSSION 
DNA damage of tumor cells caused by ionizing radiation has been a productive therapeutic 
strategy with over two-third of all cancer patients dependent on ionizing radiation therapy 
(10). This approach targets rapidly proliferating tumor cells justifying its wide usage. 
However, depending on its dosage, adverse side effects caused by radiation therapy are of 
serious concern (10). Efforts to find conditions under which low radiation exposure may 


























































































































































































































































therefore of interest. To achieve best health outcomes, lower doses of radiation are often 
used in combination with conventional chemotherapy. While this is of broad interest, this 
approach has its own limitations primary of which is the fact that in general 
chemotherapeutic drug themselves are highly cytotoxic not only for tumor cells but also 
for other healthy cells of the body. The adverse side effects of both radiation as well as 
chemotherapy pose serious threat to the recovery and quality of life of the surviving 
patient (9). Phytochemicals, such as anthocyanins, are not only safe but often desirable 
because of their antioxidant and other beneficial properties (20). An exciting development 
in tumor management is the observation that dietary phytochemicals exhibit strong 
chemopreventive properties (33). Our previous work has demonstrated that a 
standardized natural edible berry extract (NBE) is capable of prolonging survival of mice 
affected with HE (11). Thus, for certain tumors, these phytochemicals may have a role 
beyond chemoprevention where therapeutic benefits may be expected. NBE is now 
awarded FDA IND (140318), for human testing against infantile hemangioma. As such 
efforts progress, it becomes critically important to understand the mechanisms of action 
of NBE in settings involving vascular neoplasms. Furthermore, it becomes important to ask 
whether NBE may co-operate with ionizing radiation such that best outcomes may be 
obtained with radiation so weak that it is otherwise ineffective by itself.  
Otto Warburg’s proposal of the heavy reliance of cancer cells on aerobic glycolysis, as 
opposed to mitochondrial OXPHOS, for their energy supply has now evolved to recognize 
that mitochondrial function is essential for tumor survival. Thus, in addition to applying 
brakes on the cell cycle, strategies to specifically disrupt mitochondrial function of tumor 
cells are likely to be valuable (55). A combination approach to target cell cycle as well as 
mitochondrial function of tumor cells is likely to be productive especially in rapidly growing 
tumor cells heavily relying on their mitochondrial function for their sustenance. 
Bioenergetic alterations in tumor cells are diverse. While some are more glycolytic, others 
rely on OXPHOS of the mitochondria (55). This work presents first evidence on the 
strikingly hyperactive mitochondria in EOMA cells. In this work, a combination of weak XRT 
(0.5Gy) and NBE was most effective in killing EOMA cells when only doses that were safe 























































































































































































































































death, the effect was significantly enhanced by co-treatment with weak XRT. These 
observations provided the first cues for the design of in vivo rescue experiments. 
Interestingly, mitochondrial oxygen consumption rate of EOMA were three-fold more than 
that of MAE suggesting heavy reliance of these cells on their mitochondrial function. At 
dosages used, both NBE as well as weak XRT were safe for MAE. Yet NBE caused marked 
lowering of mitochondrial respiration. These results are consistent with our earlier findings 
(4). Weak XRT was also effective in blunting mitochondrial respiration. In combination, 
NBE and weak XRT severely attenuated mitochondrial function. This work is the first to 
report on such co-operative effect of a phytochemical and weak XRT on selectively limiting 
tumor mitochondrial functions in a way that favorably affects tumor outcomes in vivo. 
Glycolysis contributes to tumor cell metabolism. Compared to that of MAE cells, the rate 
of glycolysis in EOMA was two-fold higher. Specifically, in EOMA cells NBE marginally 
inhibited glycolysis. Weak XRT induced glycolysis in healthy MAE cells. This observation is 
consistent with studies testing higher doses of radiation to demonstrate an acute phase of 
induction of glycolysis (64). In EOMA cells, however, with already high baseline rates of 
glycolysis, weak XRT inhibited glycolysis in the longer-term. Inhibition of glycolysis in tumor 
cells by ionizing radiation has been reported (19). High ATP turnover, high proton leak, or 
elevated non-mitochondrial oxygen consumption may account for high basal respiration of 
the cell (27). Compared to MAE cells, EOMA cells showed 6-fold higher basal respiration. In 
the hepatocytes and cardiomyocytes, non-mitochondrial oxygen consumption constitutes 
approximately 40% of basal OCR, and in endothelial cells approximately 15% (27). In 
EOMA, non-mitochondrial oxygen consumption accounted for 15% of its basal respiration. 
Such oxygen consumption is known to contribute to reactive oxygen species (ROS) 
formation in the cell. EOMA cells, rich in ROS, rely on these oxygen derivatives for their 
growth (12). NBE inhibited both basal as well as non-mitochondrial respiration of EOMA 
cells while not affecting MAE cells. While weak XRT had no effect on basal respiration it 
inhibited non-mitochondrial respiration selectively in EOMA. A combination of NBE and 
weak XRT did not have any effect on healthy MAE cells. However, it markedly inhibited 
both basal as well as non-mitochondrial respiration in EOMA cells. While ATP production 
rate of EOMA cells were 5-fold higher than in MAE cells, ATP balance in these cells was 























































































































































































































































ATP/ADP ratio were comparable between MAE and EOMA. NBE lowered the rate of ATP 
production, depleted ATP content, elevated ADP and lowered ATP/ADP ratio. Such effect 
was selectively observed in EOMA while MAE cells remained unaffected. While weak XRT 
did not influence these parameters on its own in either cell type, it potentiated the effect 
of NBE in lowering the production rate of ATP and elevation of ADP.   
Polyphenol-induced loss of tumor mitochondrial function has been recognized as a 
physicochemical process that cancer cells cannot develop resistance against by gene 
mutation (39,48). Anthocyanins, rich in berries, are also known to influence mitochondrial 
dynamics (39). NBE elevated Drp1 in both MAE as well as in EOMA with the distinct 
contrast that in MAE such increase in fission was not associated with cytotoxicity while in 
EOMA it was. With respect to the interpretation of significance of such findings it is 
important to put into context changes in mitochondrial fusion under the same conditions. 
In MAE, NBE did not influence mitofusin 2. Thus, increased fission in the context of 
unchanged fusion had no influence on cell viability. In contrast, in EOMA cells, induction of 
fission was coupled with significant lowering on fusion resulting in loss of cell viability.  
Thus, unopposed fission killed EOMA cells. Of outstanding interest was the observation 
that weak XRT did not influence mitochondrial dynamics in both MAE as well as EOMA. 
However, selectively in EOMA, weak XRT markedly potentiated the inhibitory effect of NBE 
on fusion. Such synergistic effect is likely to explain the potentiation of EOMA cell death in 
response to a combination treatment of NBE followed by weak XRT. Fusion of the outer 
mitochondrial membrane occurs when cells are forced to rely on OXPHOS by withdrawing 
glucose as a carbon source, thus maximizing OXPHOS by stimulating complementation 
among mitochondria(35). Impaired fusion and lowered mitochondrial membrane potential 
favors mitochondrial fragmentation that is often accompanied by bioenergetic defects as 
has been evident in this work in response to combination treatment(35,49) .SIRT3 has 
been described as a mitochondria-localized tumor suppressor (30). SIRT3 helps mount 
mitochondrial adaptive response to stress, such as metabolic reprogramming and 
antioxidant defense mechanisms. It has thus been recognized that targeting SIRT3 holds 
promise in tumor management (14). Baseline SIRT3 levels in EOMA cells were observed to 


























































































































































































































































with high phosphorylated AMPK, a key signaling partner of SIRT3 (34). Phosphorylation of 
AMPK is known to be associated with depleted cellular energy levels as was evident in this 
work (31). At doses used, both NBE as well as weak XRT did not influence SIRT3 levels in 
MAE cells. Yet, NBE was effective lowering SIRT3 levels in EOMA from low to deficient. 
Weak XRT alone had not effect on SIRT3 in EOMA. However, it markedly potentiated the 
lowering effects of NBE. Plant polyphenols are known to function as natural sirtuin 
inhibitors (26). Downregulation of SIRT3 is of interest in managing human breast and 
gastric cancer (17,61). This work presents first evidence that NBE and weak XRT may work 
synergistically to downregulate SIRT3 in vascular tumor cells. The extraordinary 
significance of such downregulation with respect to tumor outcomes was highlighted in 
experiments where the therapeutic effects of such combination therapy was completely 
abrogated under conditions of pharmacological induction of SIRT3 by PQQ.  
Studies on cell biology, as discussed above, lead to the notion that a combination of NBE 
and weak XRT would be effective in improving health outcomes of 
hemangioendothelioma. Several previous studies have demonstrated that mice suffering 
from HE survive roughly for two weeks (11,21). Consistent survival outcomes were 
observed in this study. Combination therapy with NBE and weak XRT significantly extended 
lifespan to over six weeks. NBE alone also improved survival. However, weak XRT alone did 
not. Taken together, this work presents maiden evidence demonstrating the co-operative 
action of NBE and weak XRT in managing HE. The mechanism of action of this combination 
therapy includes selective targeting of mitochondrial dynamics and function of tumor cells. 
Mitochondrial-targeted antitumor therapies are likely to be productive in the management 
of HE.  
MATERIALS AND METHODS 
Cell culture. EOMA and murine aortic endothelial (MAE) cells were maintained under the 
same conditions as previously described (12,23). In brief, cells were maintained in DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin (complete media), and 























































































































































































































































carried out in cell culture media for 24 hours prior to initiating experiments. NBE is a 
proprietary mix of powdered berry extracts (PediaBerry™, NutrimiR, Columbus, OH). 
Extracellular flux and oxygen consumption rate (Seahorse™) assays. Oxygen 
Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) measurements were 
performed using a Seahorse Bioscience XF-96 instrument as described previously (16,45). 
In brief, a day prior to the experiment, the sensor cartridge was hydrated overnight using 
the calibration buffer supplied by the manufacturer (Seahorse Biosciences, Santa Clara, CA, 
USA). The NBE treated cells were seeded in the 96 well microplate in complete DMEM 
media with 4.5g/L of glucose. On the day of the experiment, the cells were washed with 
calibration buffer twice and incubated with glucose free Seahorse XF base medium 
supplemented with 25mM of glucose for 1h at 37°C in a CO2 free incubator. The injection 
ports of the sensors were filled with 20 μL of treatment or vehicle in buffer. The sensor 
was then placed into the XF-96 instrument and calibrated. After calibration, the calibration 
fluid plate was replaced with the cell plate. The measurement cycle consisted of a 2 min 
mix, 1 min wait, and a 2 min measurement. Four basal rate measurements were followed 
by sequential addition of oligomycin (8µg/ml), carbonylcyanide-3-chlorophenylhydrazone 
(CCCP, 100µM), rotenone (100µM), and antimycin A (100µM) prepared in glucose free 
Seahorse XF base medium.  Each injection was followed by four measurement cycles. The 
consumption rates were calculated from the continuous average slope of the decreased 
O2 using a compartmentalization model(36) . For any one treatment, the rates from 10 
wells were used. Rates for the wells were normalized for protein content.  
Determination of cell viability. Cell viability was measured by leakage of lactate 
dehydrogenase (LDH) from cells to media using the in vitro toxicology assay kit from Sigma 
Chemical (St Louis, MO, USA) as described (12). Cell viability was also analyzed by 
propidium iodide (PI) exclusion test. Cells were incubated with PI (2.5 mmol/L) in 
phosphate-buffered saline for 15 minutes at 37°C and with 5%CO2. Fluorescence intensity 
was determined by FACS using PI staining in the FL2 region using an Accuri C6 Flow 
Cytometer (Accuri, Ann Arbor, MI) at 530-nm excitation with a gated sample size of 10,000 


























































































































































































































































Measurement of mitochondrial membrane potential. Mitochondrial membrane potential 
changes were analyzed using the lipophilic cationic dye JC-1 (MitoProbe JC-1 Assay Kit for 
Flow Cytometry, Life technologies) per manufacturer’s instruction by flow cytometer as 
reported previously (8). 
Determination of ADP/ATP levels. Changes in the ADP/ATP ratio were measured using 
bioluminescent assay (EnzyLightTM ADP/ATP Ratio Assay Kit; BioAssay Systems) as 
described previously (42). The ATP content in each sample was corrected for the protein 
concentration that was determined with the bicinchoninic acid (BCA) protein assay 
(Pierce). 
Western blot. Immunoblotting was performed using cell lysates and the protein 
concentration determined using a BCA protein assay. Samples (15-20 μg of protein / lane) 
were separated using 4-12% SDS polyacrylamide gel electrophoresis and probed with 
Rabbit monoclonal anti-Mitofusin 2 antibody (1:1000 dilution, Cat no # ab124773, Abcam, 
Cambridge, MA), rabbit monoclonal anti-Drp1 antibody (1:1000 dilution, Cat no # 
ab184247, Abcam, Cambridge, MA), anti-OPA1 antibody (1:1000 dilution, Cat no # 1284B, 
Novus Biologicals, Centennial, CO), Anti-MFF antibody (1:500 dilution, Cat no # ab129075, 
Abcam, Cambridge, MA)  anti-phos-AMPK (1:1000 dilution, Cat no # PA5-17831, 
ThermoFisher Scientific, Grand Island, NY), anti-AMPK (1:1000 dilution, Cat no # NB100-
239, Novus Biologicals, Littleton, CO), rabbit polyclonal anti-SIRT3 antibody (1:100 dilution, 
Cat no # ab86671, Abcam, Cambridge, MA) and anti-mouse ß-actin (1:10000 dilution, Cat 
no # A5441, Lot. #055K4854 Sigma, St. Louis, MO). Bands were visualized by using 
horseradish peroxidase conjugated donkey anti-rabbit-IgG (1:2000, Cat no # NA934V, Lot # 
9583369, Amersham Biosciences, Piscataway, NJ) and anti-mouse-IgG (1:2000, Cat no # 
NA931V, Lot # 6652622, Amersham Biosciences, Piscataway, NJ) (11,12,24) and the 
enhanced chemiluminescence assay (Amersham Biosciences, Piscataway, NJ) according to 
the manufacturer’s instructions.  Pixel densitometry for individual bands was done using 
image J software. 
SIRT3 ELISA. Cells were seeded in 12-well plates at 0.1 X 106 cells/well. SIRT3 ELISA was 























































































































































































































































Biosciences, San Diego, CA) according to the manufacturer’s instructions. BCA protein 
assay was performed on an aliquot of all tested samples and the results standardized per 
milligram of protein. 
Transmission Electron Microscopy (TEM). TEM was done as per our previous report(57). 
Briefly, primary fixation of the cells was done with 3% Glutaraldehyde in 0.1M phosphate 
buffer. After rinsing in buffer, post fixation followed for 1 hour with 1% osmium tetroxide 
in 0.1M phosphate buffer. After dehydration using ethyl alcohol and acetone as an 
intermediate solvent, cells were infiltrated over the weekend in ½  acetone and ½ 
embedding media. They were then embedded in fresh resin (Embed 812, Electron 
Microscopy Sciences, Hatfield, PA). Following polymerization overnight at 60°C the blocks 
were then ready to section. All steps were done in small centrifuge tubes, including 
embedding. Thin sections were cut (80-90nm), stained with UA replacement stain, 
(Electron Microscopy Sciences, Hatfield, PA) then viewed on a Tecnai Spirit (ThermoFisher, 
Hillsboro, OR). Digital images were taken with an AMT (Advanced Microscopy Techniques, 
Danvers, MA) CCD camera. 
Ultrasound imaging. A high-frequency, high-resolution ultrasound imaging system (Vevo 
2100; Visual-Sonics, Toronto, Canada) with a MS 550D (22-55 MHz) linear array transducer 
was used as described previously(18,45,46). Mice were anesthetized using a mixture of 
1.5% isoflurane inhalant anesthesia with 95% oxygen and animals were placed in the 
supine position on a moveable, heated stage maintained at 37°C. Hair was removed from 
tumors using a depilatory cream. Ultrasound scan transmission gel was applied to the 
tumor surface and the probe was positioned on a fixed stand perpendicular to the stage. 
The image resolution was maintained at 100 µm laterally and 50 µm axially. B-mode 
mapping was performed until clearly visualized the tumor anatomical location. Each 
targeted tumor was visualized in two-dimensional (2D) imaging for the visualization of the 
tumor. Fine position adjustment was done for the highest signal intensity with continuous 
adjustment of contrast, dynamic range, and gain until the minimal noise appeared in the 
background. For tumor volume measurement, different location on the tumor was setup 
with the transducer and B-mode recordings were made with the ultrasound beam 























































































































































































































































seconds, of B-mode were saved. Color Doppler flowmetry of tumor vasculature and tumor 
feeder vessel flow were also recorded using color Doppler flow imaging (CFI) mode in 2D 
mode. 
The tumor volume was measured during post-processing. VevoLab software (Visual Sonics) 
was used to compile each 2D image slice with other acquired slices and traced the area 
and depth of the wound resulting into a volumetric data. From the real-time B-mode 
observation, the frame-wise tracing of tumor edge borders were performed. 
In vitro XRT. Cells were pretreated with NBE (200µg/ml) or vehicle (1% DMSO) for 24h. For 
the XRT exposure experiments, one multi-well plate was used as an unexposed control and 
other plates were exposed to either 0.5 (weak) or 1Gy of XRT using an XRT unit (Precision, 
north Branford, CT) (28,54). 6 or 12h after exposure with XRT, cells were collected for 
further analysis. Here NBE treated non-irradiated cells were maintained with the exact 
time points matched with NBE exposure of irradiated cells.   
In vivo weak XRT. All animal protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC) of the Ohio State University, Columbus, Ohio. Mice were 
maintained under standard conditions at 22+2°C with 12:12 dark: light cycles with access 
to food and water ad libitum. 129P/3 mice (6-8 weeks, female, Jackson Laboratories, Bar 
Harbor, ME Indianapolis, IN) were subcutaneously injected with vehicle, EOMA cells, as 
previously described (12). Mice were treated with oral gavaging of NBE (20mg/kg) and 
topical application (200mg/kg) once daily (11). Mice were radiated with 2.5Gy gamma XRT 
per dose directed at the tumor given on the 3rd, 5th and 7th day after EOMA cell injection 
for a total dose of 7.5 Gy. On the 10th day after cell injections mice were sacrificed and 
tumor volume was determined by using calipers to measure length × width × height of 
each tumor as previously described (11,21).  
Immunocytochemistry (ICC) and confocal microscopy. For immunocytochemistry, cells 
(50,000 cells/well) were seeded on a coverslip. Cells were exposed to treatment after 
adhering to the cover slips. Post treatment, all experimental groups were incubated in 
DMEM (4.5g/l glucose) containing 250nM MitoTracker™ Red CMXRos at 37° C for 30 


























































































































































































































































in PBS and fixed with 4% paraformaldehyde solution made in PBS prior to blocking with 
10% NGS. Cells were then incubated with Anti-Drp1 (1:50 dilution, Cat no # ab184247) at 
4°C overnight. Signal was visualized by subsequent incubation with fluorescence-tagged 
appropriate secondary antibodies. Fluorescent stained slides were counter stained with 
DAPI. Confocal microscopy was performed using a ZEISS LSM 880 (Germany). Co-
localization was quantified using co-localization plug-in of Zeiss software (Zen, blue 
edition) as per our previous reports(45-47). Pearson correlation coefficient was 
determined for each cell as a measure of co-localization and was expressed as means ± 
S.D. 
mtDNA copy number determination. Extracted DNAs (DNeasy Blood & Tissue Kit, QIAGEN, 
Germantown, MD) from EOMA and MAE cells exposed to different conditions were used 
to measure mitochondrial to nuclear DNA ratio using PCR format per manufacturer’s 
instructions (NovaQUANT™ Mouse Mitochondrial to Nuclear Ratio kit, EMD Millipore, 
Billerica, MA). Data was presented as mtDNA copy numbers as described previously(2).  
Mitochondrial mass determination. It was done using MitoTracker® green FM. After 
treating with NBE or vehicle for 24 hours, cell pellet was obtained by centrifugation. Cells 
were resuspended in prewarmed DMEM media containing 25nM of MitoTracker® green 
FM (Invitrogen M7514) and incubated for 30 minutes at 37°C. After incubation, cells were 
washed two times with PBS and resuspended again in fresh medium and analyzed by flow 
cytometry to access the mitochondrial mass. 
Statistical methods. Two-sided two-sample t tests were used to compare the differences 
between two groups with proper data transformation. Residual data from every test were 
investigated to ensure that the normality assumptions of the model were satisfied. 
Sensitivity analyses were also conducted using nonparametric procedures to ensure that 
the conclusions were robust to the selection of the statistical methods. The statistician was 
completely blinded about the study. A Kaplan-Meier survival analysis with log rank test 
was to compare different groups. A sample size of 5 for each group will provide at least 
80% power of detecting a 2-fold change of each miRNA at type I error α=0.01 and 
assuming a 25% Coefficient of Variation (CV) based on a two sided two sample t-test for 























































































































































































































































to identify the best dose that is approximately 1.0 standard deviation better than the next 
best dose at α = 0.05. A one-side log rank test with sample size of 5 per group provide 80% 
power at significance level of 0,05 to detect proportion of survival of 20% for control and 
80% for combined treatment at day 14. A p value of <0.05 was considered statistically 
significant for each experiment. 
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Sensitization of tumor forming endothelial cells to effects of XRT is time and dose 
dependent. 
a, EOMA and MAE cells were treated with NBE (200µg/ml) and vehicle (1% DMSO) for 6, 
12, 24 and 48h. In some treatment group, 0.5 and 1Gy of X-ray radiation was exposed for 
6h after NBE treatment schedule.  Cell viability was measured by flow cytometry using PI 
(10µg/ml) exclusion and (b) LDH toxicity assay (Sigma-Aldrich, MAK066) shows a dose 
dependent decrease in EOMA cell survival. MAE cells were included as non-tumor forming 
endothelial cell controls. The key indicates the time of sample collection after XRT or after 





























































































































































































































































NBE sensitized EOMA, not MAE, cells to weak XRT by inhibiting mitochondrial 
respiration.  
NBE/vehicle treated MAE, EOMA cells were seeded (5000cells/well) in a Seahorse XF 96 
well plate. After the indicated time points of treatment schedule Oxygen consumption rate 
(OCR) was determined during sequential treatments with oligomycin (ATP-synthase 
inhibitor; 8mg/ml), CCCP a protonophore that lowers the mitochondrial membrane 
potential to create conditions for maximal oxidative respiration (100mM), and antimycin-A 
(100mM) + rotenone (100mM) to inhibit the electron transport chain. a, Vehicle controls 
were treated with 1% DMSO. Cells were exposed to XRT alone (0.5/1.0 Gy) or in 
combination of NBE and XRT for 6h (b) and 12h (c) exposure as mentioned earlier. d, bar 
graph comparing basal OCR under all treatment conditions shows decreased OCR after 
weak XRT exposure in NBE treated EOMA cells. But there was no such observation was 


























































































































































































































































Inhibition of tumor cell glycolysis by NBE alone, and more so in combination with weak 
XRT.  
NBE/vehicle treated MAE, EOMA cells were seeded (5000cells/well) in a Seahorse XF 96 
well plate. After the indicated time points of treatment schedule extracellular acidification 
rate (ECAR) of cells was determined by Seahorse XF96 analyzer, upon sequential addition 
of oligomycin (100mM), CCCP (100mM), and antimycin-A (100mM) + rotenone (100mM). 
One of 3 experiments is shown as representation. a, Only NBE exposure significantly 
inhibits ECAR levels in EOMA cells not in MAE. b, Representative bar graph shows ECAR 
levels was further inhibited with the exposure of either weak XRT or XRT at 6h which was 
not observed in MAE cells but with longer exposure (12h), MAE cells shows significant 
reduction in ECAR level (c). The representative bar graph shows decreased ECAR after 
weak XRT/XRT exposure in NBE treated EOMA cells. But there was only with NBE with XRT 
exposure in MAE cell causes inhibition of ECAR activity. Thus 0.5Gy dose was selected for 
























































































































































































































































Blunted cellular respiration and reduced ATP production in EOMA cells. 
a, Basal respiration measured from Seahorse XF96 was significantly inhibited with weak 
XRT in NBE treated EOMA compared to MAE. b, The residual oxygen consumption also gets 
compromised with weak XRT exposure in NBE treated EOMA cells. No such effects were 
observed in non-tumor forming MAE cells. c, weak XRT exposure causes decreased rate of 
ATP production in NBE treated EOMA cells compared to no weak XRT group. All 
calculations were made using the Agilent Seahorse Software provided with the instrument. 
Results are expressed as mean ± SD (n = 6). d, Basal cellular ATP, ADP (e) and the ratio (f) 
were measured in different treatment groups using the EnzyLightTM ADP/ATP ratio assay 




























































































































































































































































Mitochondrial fission and membrane potential.  
a, Colocalization analysis of mitochondrial fission marker (Drp1, abcam, ab184247 1:200) 
and MitoTracker Red CMXRos (250nM)  in MAE and EOMA cells before and after 
treatment of NBE or XRT (n = 3-5). Scale bar = 2 m. Inset shows the cell from which the 
region of interest was taken. Scale bar = 5 m. Complete image set is presented as Sup Fig. 
2. b, Western blot images of Mfn-2 and Drp-1 protein expressions was compared between 
no-XRT group and weak XRT exposure in NBE or vehicle treated MAE/EOMA cells. (c) Bar 
graph for Drp-1 and (d) Mfn-2 protein expressions, normalized with β-actin. e, 
Mitochondrial copy numbers of MAE and EOMA cells exposed to vehicle control or NBE. In 
addition, mitochondrial copy numbers determination was done o EOMA cells were further 
exposed with weak XRT with or without NBE (n = 3). f, Loss of mitochondrial membrane 
potential in EOMA and MAE cells exposed with weak XRT with or without NBE, as assessed 
by JC-1 flow cytometry. Cells were collected 6h after XRT exposure with or without NBE 
treatment and stained with 2.5µM of JC-1 for 15mins. The ratio of red to green shows 
significant decrease of mitochondrial membrane potential in combined treatment of NBE 
& XRT than XRT alone. Results are expressed as mean ± SD (n = 6). g, Representative 
images of cell populations analyzed by the Flow Cytometer (Beckman-Coulter), using a 488 
laser, following standard protocols provided by JC-1 manufacturers. h, Intensity calculation 
and i, Representative airyscan confocal (ZEISS LSM 880, Germany) images of cells 























































































































































































































































compared with untreated MAE cells.j, Flow cytometric profiles of mitochondrial mass 
levels in EOMA and MAE cells after exposed to NBE, by Mito Tracker green FM (25nM). k, 
Median fluorescence intensity (MFI) of Mito Tracker green FM of EOMA and MAE cells 
























































































































































































































































SIRT3 depletion responsible for inducible death of EOMA. 
a, Representative image of intracellular SIRT3 localization in MAE, EOMA cells. b, EOMA 
and MAE cells were seeded in equal number (100000 cells/well) in 12 well plate. After the 
mentioned treatment schedule cells were isolated and measured for SIRT3 level using 
SIRT3 ELISA kit. SIRT3 levels was normalized to the number of cells seeded per well. Sirt3 
levels were significantly reduced in cellular supernatant of EOMA compared to MAE, it was 
further reduced when treated with NBE alone or combined exposure of NBE and weak XRT 
in EOMA cells.  c, Pyrroloquinoline quinone (PQQ), chemical activator of Sirt 3 causes 
induction of Sirt3 in dose dependent manner in both MAE and EOMA, (d) Significant cell 
death was observed in EOMA cells with 30µM as shown by PI positivity. (e) 12h 
pretreatment with PQQ (20µM) significantly rescued the cellular survival of EOMA cells 
compared to combined exposure of NBE and weak XRT and subsequently the level of Sirt3 
were found to be significantly elevated (f) at that point. Results are expressed as mean ± 
SD (n = 3). (g) Western blot images of SIRT3 protein expression was compared between 
control, vehicle control (DMSO), LC-0296 (10μM) and NBE treated groups in EOMA cells. 
Signal intensities of SIRT3 protein is normalized with β-actin. Results are expressed as 
mean ± SD (n = 3). (h) Percentage of PI fluorescence expressing cells were counted by flow 
cytometry, after staining NBE and LC-0296 treated EOMA cells with propidium iodide 




























































































































































































































































AMPK phosphorylation caused by severe depletion of SIRT3 compromises mitochondrial 
respiration in EOMA cells.   
a, Western blot shows elevated ratio of phospho-AMPK to AMPK in EOMA cells compared 
to MAE. PQQ treatment reduces the AMPK activation by inhibiting phosphorylation in both 
MAE and EOMA cells. b, Western blot images of phospho-AMPK and AMPK in NBE alone or 
combined exposure of NBE and weak XRT. c, Intensity calculation confirms either NBE 
alone or in combination with weak XRT increases the phosphorylation of AMPK in EOMA 
cells. Results are expressed as mean ± SD (n = 3). d, OCR data shows, pretreatment with 
PQQ rescued the combined effect of NBE and weak XRT.  Results are expressed as mean ± 


























































































































































































































































Improved survival of mice with HE tumor. 
Syngeneic 6-8 week old female 129 P/3 mice received a subcutaneous injection of EOMA 
cells. Mice were treated with NBE oral gavage (20mg/kg) and topical application 
(200mg/kg) once daily. XRT exposure using irradiator RS2000 was carried out with 2.5Gy 
gamma XRT per dose directed at the tumor given on the 3rd, 5th and 7th day after EOMA 
cell injection for a total dose of 7.5 Gy. a, ultrasound imaging of animals from each group 
(n=5) were performed on a Vevo2100 system (Toronto, Ontario, Canada) using high 
frequency linear array transducers operating between 8 and 17 MHz. b, Tumor volume 
was quantified using calipers (length x width x height). Significantly reduced tumor growth 
was observed at day 10 in NBE +XRT treated group compared to others. c, tumor blood 
flow was analyzed using Vevo2100 system shows significant difference at day 10 after 
NBE+XRT combined treatment compared to other groups. d, Representative images of 
tumor in different treatment group. e, H&E staining of tumor section after 10 day of cell 
injection shows decreased cellular granularity. f, Kaplan-Meier survival curve analyzed by 
log-rank analysis shows mice treated with vehicle, XRT only, NBE only and NBE + XRT. 
Results are expressed as mean ± SD (n = 5). Here NBE only and NBE + XRT treatment have a 
significant survival advantage compared to vehicle control, * p <0.05. Also, NBE + XRT 



























































































































































































































































SUPPLEMENTARY FIGURE 1 
Decreased mitochondrial abundance after NBE treatment 
a, Representative images of cells stained with mitotracker red shows mitochondrial 
abundance in EOMA compared to MAE. Treatment with NBE and XRTweak changed 
mitochondrial appereances in EOMA cells. b, Transmission electron microscopy 
observation of the mitochondria in (Top) MAE, EOMA cells and EOMA cells treated with 
NBE+XRTweak. Bottom panel represent the mitochondrial morphology of EOMA cells before 
and after treatment of NBE or XRTweak. Bar graph showing the abundance of mitochondria 
in above-mention conditions normalized with mtDNA copy number. (c) Magnified 
transmission electron microscopy images of the mitochondria as shown in (panel b). Top 
panel represent the mitochondrial morphology EOMA cells and EOMA cells treated with 
NBE. Bottom panel represent the mitochondrial morphology of EOMA cells treatment of 


























































































































































































































































SUPPLEMENTARY FIGURE 2 
Confocal analysis of mitochondrial fission 
High-resolution confocal images of mitochondrial fission marker (Drp1) (green) and 
MitoTracker Red CMXRos (red) in MAE and EOMA cells before and after treatment of NBE 























































































































































































































































Supplementary figure 3: Induced phosphorylation of DRP-1 with NBE treatment 
a, Western blot images of cellular caspase 9 and cleaved caspase 3 protein expression was 
compared between no-XRT group and weak XRT exposure in NBE or vehicle treated 
MAE/EOMA cells.  Relative bar graph for cleaved caspase 3 protein expressions, 
normalized with β-actin. Results are expressed as mean ± SD (n = 3). b, Detection of P-
DRP1 and DRP1 protein expression in NBE or vehicle treated MAE/EOMA cells by Western 
blot. Signal intensities of P-DRP1/DRP1 protein is normalized with mitochondrial mass. 























































































































































































































































SUPPLEMENTARY FIGURE 4 
Additional mitochondrial fission and fusion markers investigation in EOMA and MAE 
cells. 
Mitochondrial fission marker protein, Mitochondrial Fission Factor (MFF) was significantly 
induced and mitochondrial fusion marker protein, Dynamin-like protein (OPA1) was 
significantly reduced with NBE and XRTweak treatment in EOMA cells. Results are expressed 
as mean ± SD (n = 3).    
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